Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.43 |
| ▸ | BTK | Q06187 | 2/20 | 0.40 |
| ▸ | MAPK8 | P45983 | 4/20 | 0.37 |
| ▸ | SYK | P43405 | 9/20 | 0.36 |
| ▸ | KIT | P10721 | 1/20 | 0.36 |
| ▸ | FLT3 | P36888 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.34 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.34 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1935846 | 1.00 | ROCK2 (0.43) | ROCK2ROCK1BTKMAPK8SYK | |
| SCHEMBL1938096 | 0.89 | SYK (0.40) | BTKMAPK8SYKKITFLT3 | |
| SCHEMBL1938097 | 0.89 | SYK (0.40) | BTKMAPK8SYKKITFLT3 | |
| SCHEMBL1938085 | 0.85 | ROCK2 (0.47) | ROCK2ROCK1BTKSYKGSK3B | |
| SCHEMBL1938084 | 0.85 | ROCK2 (0.47) | ROCK2ROCK1BTKSYKGSK3B | |
| SCHEMBL1937258 | 0.82 | GAA (0.37) | — | |
| SCHEMBL1937259 | 0.82 | GAA (0.37) | — | |
| SCHEMBL1938169 | 0.81 | ROCK2 (0.62) | ROCK2ROCK1BTKMAPK8SYK | |
| SCHEMBL1938167 | 0.81 | ROCK2 (0.62) | ROCK2ROCK1BTKMAPK8SYK | |
| SCHEMBL1937890 | 0.81 | ROCK2 (0.53) | ROCK2ROCK1MAPK8SYKKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166161-A1 | HETEROCYCLIC CARBOXAMIDE COMPOUNDS | ASTELLAS PHARMA INC. (JP) | 2011-07-07 | — | — | US | disclosed |
| EP-2331507-A2 | HETEROCYCLIC CARBOXAMIDE COMPOUNDS | Astellas Pharma Inc. (JP) | 2011-06-15 | — | — | EP | disclosed |
| WO-2010032875-A2 | HETEROCYCLIC CARBOXAMIDE COMPOUNDS | ASTELLAS PHARMA INC. (JP) | 2010-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166161-A1 | HETEROCYCLIC CARBOXAMIDE COMPOUNDS | ROCK1, ROCK2, RHOT2 | ROCK2 2/4885ROCK1 1/4885BTK 500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.